RENB: Rega marang dodolan Enochian BioSciences

Tandha merek Enochian BioSciences (RENB)

The development of AI platforms for cancer therapy involves high scientific risks and patent disputes for Renovaro Inc. (RENB). The P/S ratio visualizes the dynamics of market valuation relative to revenue, where serves as the base value of the parameter. The company's genetic potential provides stability through partnerships; however, the lack of operating leverage and high laboratory costs currently render the business unprofitable.

RENB (Renovaro Inc.) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 14.11.2026

Rincian analitis perusahaan renovarobio.com (RENB)

- rega saham lan konsensus proyeksi valuasi:
Bagan owah-owahan rega Renovaro|RENB - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Nilai pasar Renovaro|RENB - Nilai Total Perusahaan
- data nilai buku modal saham:
Ekuitas saben Saham Renovaro|RENB - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku renovarobio.com|RENB - Gunggung Aset Perusahaan
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Renovaro Inc.|RENB - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Renovaro Biosciences|RENB - Utang perusahaan|Rasio utang marang aset resik Renovaro|RENB - Utang jangka dawa perusahaan|Utang jangka cendhak Renovaro|Rasio jangkoan perantara renovarobio.com
- indikator pendapatan resik lan kelipatan nilai:
RENB - Bathi resik|Prakiraan bathi perusahaan Renovaro Inc.|RENB - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep Renovaro|RENB - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Renovaro Inc.|RENB - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Renovaro|RENB - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan renovarobio.com|RENB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Renovaro Inc.
- data total pendapatan lan volume dodolan:
RENB - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Renovaro|RENB - Multiplikator P/S|Rasio rega marang prakiraan pendapatan RENB
Analisis fundamental perusahaan:Renovaro Inc., RENB
Sampel barang Renovaro Inc.

Evaluating the scale of Renovaro Inc. (RENB) via the P/S ratio compares market capitalization to annual sales volume. This price/sales metric measures the cost of one dollar of revenue, allowing for the determination of asset overvaluation. The price/sales trend captures market expectations regarding the commercialization of genetic developments. Intellectual capital in the field of cancer immunotherapy ensures business resilience, transforming current sales into a long-term foundation of value.

Pesaing Renovaro Inc.

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Rasio rega marang pendapatan xiliotx.com XLO|Mural Bio - Rasio rega marang pendapatan|KAPA - Rasio rega marang pendapatan|OnKure Therapeutics (OKUR) - Kapitalisasi marang pendapatan|GDTC: Multiplikator P/S|Rega marang dodolan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Multiplikator P/S|Kapitalisasi marang pendapatan Tharimmune Corp (THAR)|Multiplikator P/S ADVB|GNPX - Rega marang dodolan|Rasio rega marang pendapatan calidibio.com CLDI|SBFM - Kapitalisasi marang pendapatan|XBIO - Rasio rega marang pendapatan|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd